EGFR‐targeted CAR‐T cells are potent and specific in suppressing triple‐negative breast cancer both in vitro and in vivo

OBJECTIVES: Triple‐negative breast cancer (TNBC) is well known for its strong invasiveness, rapid recurrence and poor prognosis. Immunotherapy, including chimeric antigen receptor‐modified T (CAR‐T) cells, has emerged as a promising tool to treat TNBC. The identification of a specific target tumor a...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Lin, Zheng, Zao‐zao, Liu, Jun‐yi, Chen, Yu‐jie, Ding, Jian‐cheng, Xia, Ning‐shao, Luo, Wen‐xin, Liu, Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196685/
https://www.ncbi.nlm.nih.gov/pubmed/32373345
http://dx.doi.org/10.1002/cti2.1135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196685/
https://www.ncbi.nlm.nih.gov/pubmed/32373345
http://dx.doi.org/10.1002/cti2.1135

Ejemplares similares